Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

You may be eligible if

• 1. Between 18 and 75 years old AND
• 2. Diagnosed with Modified KDIGO Stage 2 AKI within the first 10 days after injury AND
• 3. Admitted to Intensive Care Unit or Intermediate Medical Unit AND
• 4. Received at least 3 units of any blood product within 6 hours of admission for trauma OR 15% or greater burn area OR any electrical burn OR any crush injury AND
• 5. Expected to survive at least 24 hours after diagnosis of KDIGO Stage 2 AKI AND
• 6. Patient or patient's Legally Authorized Representative (LAR) has voluntarily signed the informed consent.
• 1. Incarcerated individuals
• 2. Pregnant and lactating females
• 3. TBI deemed non-survivable by the trauma or neurosurgery attending physician
• 4. Hemodynamically unstable and requiring vasopressors for blood pressure support (systolic blood pressure ≥90 mmHg) during the 30-minute period prior to investigational product (IP) thawing/preparation
• 5. Pre-existing chronic kidney disease or acute kidney failure.
• 6. Pre-existing chronic liver disease.
• 7. Known immunodeficiency or concurrent use of potentially immunosuppressive medications at doses likely to result in an immunosuppressed status.
• 8. Active malignancy.
• 9. Known allergy to dimethyl sulfoxide or human serum albumin.
• 10. No available intravenous access (peripheral or central) of at least 22-gauge needle that can be utilized exclusively for IP during the time of planned infusion.
• 11. Clinical condition that would be anticipated to deteriorate with IV administration of 250 ml of crystalloid.
• 12. Known Do Not Resuscitate (DNR) prior to randomization